A Single and Multiple Ascending Dose Study in Healthy Subjects to Assess the Safety, Tolerability, Pharmacokinetics (PK) and Pharmacodynamics (PD) of KP-1199

Analgesia Clinical Trial

Official title:

A Randomized, Placebo- and Active-Controlled, Double-Blind, Single and Multiple Ascending Dose Study in Healthy Adults to Determine the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of KP-1199

Clinical Trial Details — Status: Terminated

Administrative data

• NCT number: NCT03880487
• Other study ID #: KP-1199-CP-001
• Secondary ID: CDMRP-OR 160158
• Status: Terminated
• Phase: Phase 1
• Start date: March 12, 2019
• Est. completion date: April 21, 2020

Study information

• Verified date: February 2021
• Source: Kalyra Pharmaceuticals, Inc.
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This is a Phase I, randomized, placebo and active-controlled, double blind, single and multiple ascending dose study in healthy adults to evaluate the safety, tolerability, pharmacokinetics and preliminary efficacy of KP-1199

Recruitment information / eligibility

• Status: Terminated
• Enrollment: 26
• Est. completion date: April 21, 2020
• Est. primary completion date: April 21, 2020
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 18 Years to 45 Years

Eligibility

Inclusion Criteria:

• Healthy Adult 18-45 years of age at time of screening, inclusive.

• Have a body mass index (BMI) between 18.0 and =32 kg/m2, inclusive, and a weight of =50 kg at screening.

• Be determined to be healthy on the basis of a pre-study physical examination, medical history review, vital sign measurements, and the results of laboratory tests.

• For both male and females: using acceptable method of birth control

• If Female: not-pregnant or not breast feeding and not planning on becoming pregnant

• All prescribed medication must have been stopped at least 14 days prior to admission to the clinical research site. An exception is made for hormonal contraceptives, which may be used throughout the study.

• All over-the-counter medication, vitamin preparations and other food supplements, or herbal medications (eg, St. John's Wort) must have been stopped at least 14 days prior to admission to the clinical research site.

• Must be adequately informed and understand the nature and risks of the study and must provide written informed consent prior to enrollment at screening.

Exclusion Criteria:

• Subjects who participate in one part of the study are not eligible to participate in subsequent parts of the study.

• Women who are pregnant, lactating, or planning to attempt to become pregnant during this study or within 90 days after the follow-up visit.

• Males with female partners who are planning to attempt to become pregnant during this study or within 90 days after the follow-up visit.

• History or evidence of significant clinical or psychiatric disorder, condition, or disease that, in the opinion of the Investigator would pose an unacceptable risk to the subject safety or interfere with the study evaluations, procedures, or completion of the study.

• Documented congenital QT syndrome, and/or corrected QT interval (Fridericia correction; QTcF) at screening or first admission > 450 ms.

• Positive screening test for hepatitis B surface antigen, anti-hepatitis C virus antibodies or anti-human immunodeficiency virus 1 and 2 antibodies.

• History of drug allergy diagnosed by a physician.

• Use of tobacco within 30 days prior to the first study drug administration.

• History of alcohol consumption exceeding 2 standard drinks per day on average.

• Routine or chronic use of more than 0.5 grams of acetaminophen daily.

• History of donation of more than 450 mL of blood within 60 days prior to dosing in the clinical research site or planned donation before 30 days has elapsed since intake of study drug.

• Plasma or platelet donation within 7 days of dosing

• Use of any investigational drug or device within 30 days of the first dose of study.

Related Conditions & MeSH terms

• Analgesia

Intervention

Drug:
• KP-1199
Single dose and Multiple ascending doses of KP-1199 oral capsules
• Placebo oral capsule
Single dose and Multiple dose identical to active treatment but without KP-1199.
• Oxycodone oral capsule
10 mg Oxycodone Capsules

Locations

Country	Name	City	State
United States	PRA Health Sciences	Salt Lake City	Utah

Sponsors (3)

Lead Sponsor	Collaborator
Kalyra Pharmaceuticals, Inc.	PRA Health Sciences, United States Department of Defense

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Number of Participants with Treatment Emergent Adverse Events	Number of treatment related adverse events as determined by abnormal clinical laboratory tests, vitals signs, physical exam, ECG parameters	Part 1: From Day 1 through Day 6, Part 2: From Day 1 through Day 11, Part 3: From Day 1 through Day 12
Secondary	Pharmacokinetic Profile of KP-1199 to measure plasma concentration of KP-1199	Maximum Observed Plasma Concentration (Cmax)	Part 1: Day 1 (pre-dose through 4 hours after dose administration), Part 2: (pre-dose through Day 8), Part 3: (pre-dose through Day 7)
Secondary	Pharmacokinetic Profile of KP-1199 to measure Time to Maximum plasma concentration of KP-1199	Time to Maximum Plasma Concentration (Tmax)	Part 1: Day 1 (pre-dose through 4 hours after dose administration), Part 2: (pre-dose through Day 8), Part 3: (pre-dose through Day 7)
Secondary	Pharmacokinetic Profile of KP-1199 to measure area under curve plasma concentration of KP-1199	Area Under the Concentration-time Curve Up to Time (t), where t is the last point with concentrations above the lower limit of quantitation (AUC0-t) Area Under the Concentration-time Curve for 1 dosing interval of a multiple dose regimen (AUCtau)	Part 1: Day 1 (pre-dose through 4 hours after dose administration), Part 2: (pre-dose through Day 8), Part 3: (pre-dose through Day 7)
Secondary	Pharmacokinetic Profile of KP-1199 to measure plasma terminal half-life concentration of KP-1199	The Apparent Terminal Elimination Half-life (t1/2)	Part 1: Day 1 (pre-dose through 4 hours after dose administration), Part 2: (pre-dose through Day 8), Part 3: (pre-dose through Day 7)
Secondary	Pharmacokinetic Profile of KP-1199 to measure the trough plasma concentration of KP-1199	Trough Plasma Concentration (Ctrough)	Part 1: Day 1 (pre-dose through 4 hours after dose administration), Part 2: (pre-dose through Day 8), Part 3: (pre-dose through Day 7)
Secondary	Pharmacodynamic Effects of KP-1199 using Cold Pressor Test to measure pain threshold	Time to feel first pain ("pain threshold" measured in seconds)	Part 3: Day 1, Day 3, Day 5 and Day 7 (pre-dose through 6 hours after dose administration)
Secondary	Pharmacodynamic Effects of KP-1199 using Cold Pressor Test to measure pain tolerance	Time to withdrawal of hand from cold water ("Pain tolerance" in seconds)	Part 3: Day 1, Day 3, Day 5 and Day 7 (pre-dose through 6 hours after dose administration)
Secondary	Pharmacodynamic Effects of KP-1199 using Cold Pressor Test	Pain tolerance will be measured at time of hand withdrawal using a 11-point (0-10) Numeric Pain Rating Scale (NPRS) where "0 (no pain) to 10 (worst pain)"	Part 3: Day 1, Day 3, Day 5 and Day 7 (pre-dose through 6 hours after dose administration)
Secondary	Pharmacodynamic Effects of KP-1199 using Ultraviolet Burn Model (UVB)	Neurosensory Testing (change in neurosensory assessments of the skin at site of ultraviolet burn)	Part 3: Day 1, Day 3, Day 5 and Day 7 (pre-dose through 6 hours after dose administration)